The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the rationale for the VERIFY study (NCT05210790), a Phase III trial assessing the safety and efficacy of rusfertide versus placebo in patients with polycythemia vera (PV). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; AstraZeneca: Research Funding; ItalPharma: Research Funding; Novartis: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Promedior: Research Funding; CTI BioPharma Corp.: Research Funding; Gilead: Research Funding; Sierra Oncology: Consultancy, Research Funding; Roche: Research Funding; Protagonist Therapeutics: Research Funding; PharmaEssentia: Research Funding; Blueprints Medicines Corp.: Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Pragmatist: Consultancy; Constellation Pharmaceuticals: Consultancy.
